Major Depressive Disorder Clinical Trials in Cedarhurst, New York
4 studies are recruiting for major depressive disorder in Cedarhurst, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Neurocrine Clinical Site, Cedarhurst, New York
- Locations
- 35 in total
- Run by
- Neurocrine Biosciences
-
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…
- Stage
- Phase 2
- Ages
- 18 to 64
- Site
- Neurobehavioral Research, Inc., Cedarhurst, New York
- Locations
- 34 in total
- Run by
- Syndeio Biosciences, Inc
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…
- Stage
- Phase 2
- Ages
- 18 to 64
- Site
- Neurobehavioral Research, Inc, Cedarhurst, New York
- Locations
- 32 in total
- Run by
- Syndeio Biosciences, Inc
-
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Neurocrine Clinical Site, Cedarhurst, New York
- Locations
- 106 in total
- Run by
- Neurocrine Biosciences
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.